The addition of another drug to the suite of COVID-19 medicines available in New Zealand is good news for patients and for the health system, Health Minister, Andrew Little said today.
“Preventing people from getting COVID-19 in the first place, through vaccinations, social distancing and mask-wearing, is still the best protection for people and for keeping the health system free for those who need it,” Mr Little said.
“But we need medicines for those who do get sick, which is why I am very pleased that the national pharmaceuticals-buying agency Pharmac has secured supplies of another drug shown to work against the COVID-19 virus.”
Baricitinib is the fifth drug Pharmac has secured, and sits alongside remdesivir, tocilizumab, molnupiravir and Ronapreve as treatments doctors can turn to to help people with a range of COVID-19 symptoms.
“Like tocilizumab, baricitinib can be used to treat patients who are very sick, as it reduces the severity of symptoms and cuts time in hospital and reduces the likelihood of death,” the Minister said.
“Pharmac expects to receive 500 doses of baricitinib this month, which is important because there is a global shortage of tocilizumab and this gives clinicians another option.”
It has yet to be approved by Medsafe for use against COVID-19, but clinicians will be able to use it immediately under Section 25 of the Medicines Act.
